Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Maternal iron deficiency anaemia influences haematologic status during infancy

05 Sep 2019

Children born to mothers with iron deficiency anaemia are at increased risk of developing an iron deficiency or anaemia during late infancy, a study has found.

The study included 359 infant–mother pairs, with the mothers having had schistosomiasis during pregnancy and randomized to treatment with praziquantel or placebo at 16 weeks’ gestation. Haemoglobin, serum ferritin (SF), soluble transferrin receptor (sTfR), hepcidin, C-reactive protein and interleukin-6 were measured in maternal and infant blood.

Researchers evaluated the relationship between both maternal praziquantel treatment and anaemia aetiology and infant iron status. They found maternal iron-deficiency anaemia to be associated with a heightened risk of infant anaemia at 6 months of age.

Babies born to mothers with the lowest levels of circulating hepcidin during gestation, which is a possible marker for iron deficiency, had higher sTfR:SF levels and lower haemoglobin levels at 12 months of age.

Maternal noniron-deficiency anaemia (NIDA) did not affect infant anaemia risk or iron status. Neither did maternal treatment for schistosomiasis influence infant haematologic status.

According to the researchers, iron status during infancy is likely influenced by both newborn iron endowment and the availability of iron in breast milk and complementary foods.

The current finding that maternal iron-deficiency anaemia is another potential contributor to infant haematologic status underscores the value of maternal iron nutriture and the need for improved preconceptual maternal iron status and better compliance with iron supplementation prenatally and postnatally, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.